SYHA1813

· Shanghai Runshi Pharmaceutical Technology Co., Ltd

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SYHA1813, covering 2024-11-08 to 2024-12-18. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma [Phase 2]